Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

10x Genomics (TXG) FCF Margin (2018 - 2025)

Historic FCF Margin for 10x Genomics (TXG) over the last 8 years, with Q4 2025 value amounting to 23.49%.

  • 10x Genomics' FCF Margin rose 292200.0% to 23.49% in Q4 2025 from the same period last year, while for Dec 2025 it was 20.24%, marking a year-over-year increase of 211800.0%. This contributed to the annual value of 20.24% for FY2025, which is 211800.0% up from last year.
  • According to the latest figures from Q4 2025, 10x Genomics' FCF Margin is 23.49%, which was up 292200.0% from 28.54% recorded in Q3 2025.
  • In the past 5 years, 10x Genomics' FCF Margin ranged from a high of 28.54% in Q3 2025 and a low of 42.74% during Q1 2022
  • Its 5-year average for FCF Margin is 10.26%, with a median of 11.55% in 2021.
  • In the last 5 years, 10x Genomics' FCF Margin soared by 1198200bps in 2021 and then crashed by -286700bps in 2022.
  • Quarter analysis of 5 years shows 10x Genomics' FCF Margin stood at 15.2% in 2021, then decreased by -10bps to 16.65% in 2022, then surged by 173bps to 12.13% in 2023, then tumbled by -147bps to 5.74% in 2024, then surged by 510bps to 23.49% in 2025.
  • Its FCF Margin was 23.49% in Q4 2025, compared to 28.54% in Q3 2025 and 9.33% in Q2 2025.